Tasly Pharmaceutical Group Co.,Ltd. Posted 410.2 Million Yuan Net Loss in First Three Quarters of 2022

Tasly Pharmaceutical Group Co.,Ltd. (天士力医药集团股份有限公司) (600535.SH) reported a net loss of 410.2 million yuan in the first three quarters of 2022, reversing a net profit of 1.5 billion yuan for the same period in the previous year.

Meanwhile, the company posted 6.1 billion yuan in revenue, up 5.7% year-on-year.

At the end of the reporting period, it had 16.3 billion yuan in total assets and 3.8 billion yuan in total liabilities, with a liability-to-asset ratio of 23.3%.